Recent studies have highlighted the potential of GLP-1 drugs, such as Ozempic and Wegovy, in treating Parkinson's disease. A notable study, the LIXIPARK phase 2 trial, demonstrated that the GLP-1 receptor agonist lixisenatide, developed by French pharmaceutical group Sanofi, could reduce motor disability in Parkinson's patients over a 12-month period. This French-backed trial, which was placebo-controlled and involved participants with early Parkinson's disease, has sparked optimism in the medical community. The findings suggest that lixisenatide and possibly other GLP-1 drugs could slow the progression of Parkinson's, marking a significant development in the management of a condition that affects millions worldwide. The research, published in the New England Journal of Medicine, has been described as a potential breakthrough in the fight against Parkinson's, offering hope for disease modification where previous treatments have failed.
šØSTUDY: OZEMPIC SLOWS PARKINSON'S? A study unveils that Lixisenatide, related to diabetes drug Ozempic, may slow Parkinson's disease. French researchers observed significant symptom deceleration in a year-long trial involving 156 participants compared to those on a placebo.ā¦ https://t.co/J3Q3oHklEF
šØSTUDY: OZEMPIC RELATIVE SLOWS PARKINSON'S A study unveils that Lixisenatide, related to diabetes drug Ozempic, may slow Parkinson's disease. French researchers observed significant symptom deceleration in a year-long trial involving 156 participants compared to those on aā¦ https://t.co/kypw3o68z4
A medication used to treatĀ diabetesĀ slowed the progression of motor issues associated withĀ #Parkinson'sĀ disease. https://t.co/wMnLhCtJr5
Original Article: Trial of Lixisenatide in Early Parkinsonās Disease (LIXIPARK phase 2 trial) https://t.co/2ancdAqO9i Editorial: GLP-1, Parkinsonās Disease, and Neuroprotection https://t.co/ZaFfYyvEP9 #Neurology https://t.co/h6Ds5wVSHu
#GLP1 -agonist Lixisenatide promising neuroprotective effects shown in pre-clinical trial in Early Parkinsonās Disease | New England Journal of Medicine. https://t.co/0oq8bt61FF
Could the GLP-1 drug lixisenatide be disease modifying in Parkinson disease? https://t.co/LuvkgPYfD0 @NEJM #NeuroTwitter #Parkinsons https://t.co/Xbw4uBMRDl
A GLP-1 medication from French drugmaker Sanofi ā similar to Ozempic ā was found to slow Parkinsonās in a small mid-stage trial. https://t.co/9Lvkufounw
A drug used to treat diabetes slowed the progression of motor issues associated with Parkinson's disease, a study published in the New England Journal of Medicine said Wednesday. https://t.co/wlT3nnArKM
A new study finds GLP-1 drugs may be used to slow down Parkinson's disease. "If you're talking to someone that has Parkinson's and you can talk about slowing these symptoms down at least 12 months, that's an incredible amount of quality of life for them," says @kavitapmd: https://t.co/yfNXxQelmR
A diabetes drug related to the latest generation of obesity drugs can slow the development of the symptoms of Parkinsonās disease https://t.co/cvXi4LtNzt
Trial of Lixisenatide in Early Parkinsonās Disease https://t.co/THoEco8r9F https://t.co/nryIfm0fW4
GLP-1 drugs are showing early potential to help people with Parkinsonās disease, according to new study results. https://t.co/d41ZKpFs9S
Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial https://t.co/EJLyvq5Bac
Parkinsonās disease may be helped by GLP-1 drug, new study finds by @elaineywchen https://t.co/kvo0q84tjD
A drug used to treat #diabetes has slowed the progression of motor issues associated with #Parkinsonās disease, a study published in the New England Journal of Medicine says. https://t.co/3fj0bQLpTV
Academic trial suggests modest GLP-1 effect in Parkinson's disease, but questions remain https://t.co/Gr3cHEEZC6
A diabetes drug may be able to slow the progression of Parkinsonās disease, representing a āsignificant step forwardā in the future management of the condition, a new study suggests. https://t.co/l9kgf83ZXC
Diabetes medication may slow progress of Parkinsonās disease in trial https://t.co/5OdgJf0sJk
class effect? super detailed story by @MaxGelman exploring unanswered Qs re: NEJM paper about a GLP-1 in Parkinson's (probably not the one you're thinking about) Academic trial suggests modest GLP-1 effect in Parkinson's disease, but questions remain - https://t.co/h3vTKzkSYk
Intriguing piece from Max Gelman on a GLP-1 success in Parkinson's, with human data from an academic study. Gelman explains why they used lixisenatide and the blood-brain issues. Another sign that GLP-1 has positive effects we don't fully understand. Pipelines in a product.ā¦
Diabetes medication appears to slow progress of Parkinsonās disease in French-backed trial https://t.co/AuVHP2brUX
Great reporting on the newest data on #GLP1s , specifically lixisenatide for Parkinsonās, in the context of previously failed liraglutide (for dementia) ā¦@elaineywchenā© ā¦@statnewsā© https://t.co/4bp6vn49do
š“ An Ozempic-like drug slows down Parkinsonās symptoms and could protect against disease progression, a study suggests https://t.co/i66DcUZdHn
A small study of @Sanofiās lixisenatide has suggested that the GLP-1 agonist could slow down the progression of #Parkinsons disease. https://t.co/dHVSFHTCPT
Diabetes drug shows promise against Parkinson's in clinical study @nejm https://t.co/FEhAf78akZ
Diabetes drug offers hope to Parkinsonās sufferers: āThe results will renew attention on the possible effectiveness of lixisenatide, which is made by French pharmaceutical group Sanofi, and other so-called GLP-1 drugs against neurodegenerative conditions.ā https://t.co/0DTw5V1e0X
Diabetes drug shows promise against Parkinson's in clinical study. Parkinson's is a devastating nervous system disorder affecting 10 million people worldwide, with no current cure https://t.co/rnlWhaECwH https://t.co/mvTugWPxyY
Trial of Lixisenatide (GLP-1) in Early Parkinsonās Disease GLP-1 the neurodegen cure? There has to be a Korean company more advanced than any of us realize working on this ready to harvest a $500M raise from US blue chip investors?!?! https://t.co/JLWMxmRPZq https://t.co/2gXO9xgoVp
Trial of Lixisenatide in Early Parkinsonās Disease GLP-1 receptor agonist may slow the progression of early Parkinsonās disease. https://t.co/2J2gNQFN3q
Iām far from a mvmt disorder expert, but this review of a new RCT investigating GLP-1RA for Parkinson's seems measured and fair. I am an expert in the clinical use of GLP1 therapies, and Iām more optimistic: Lixisenatide is a low-potency incretin, and potency makes the benefit. https://t.co/6pBGZKLtMa
Big news with positive result announced for a randomized study of a GLP-1 agonist for Parkinson's just released @NEJM. A new era for Parkinson's or alternatively, more questions than answers raised by Meissner and colleagues. Key Points: - This multi-center French trial studiedā¦ https://t.co/awwNZFc11v
Breakthrough in fight against Parkinson's as scientists find Ozempic-like weight loss jabs slow onslaught of crippling disease https://t.co/ZB1dJdzcQ2 https://t.co/GUgPfPRpdh
New trial results add to the growing body of data that suggests GLP-1 drugs may also be helpful in treating Parkinsonās https://t.co/wkEgqeXOl1
In the placebo-controlled LIXIPARK phase 2 trial involving persons with Parkinsonās disease, the subcutaneous GLP-1 receptor agonist lixisenatide was associated with reduced motor disability over a period of 12 months. Read the full trial results: https://t.co/2ancdAqO9i https://t.co/2h5n4HiksK
Lixisenatide in people with early #Parkinsons disease with non-motor involvement-less progression compared to placebo https://t.co/DQI2JeytU0
The booming class of GLP-1 drugs that includes Ozempic and Wegovy is also showing early potential to help with Parkinsonās disease, a new study suggests. https://t.co/eKVOWizOP9
Some exciting new GLP-1 drug randomized trial evidence for *potential* disease-modifying impact on #Parkinsons disease (there are none). No progression of motor disability in the Rx group for 12 months. https://t.co/FCNjfIiZT5 https://t.co/NPusWtLXRO